Your shopping cart is currently empty

GHN105 is an orally active STING inhibitor that suppresses STING-dependent IFN-β secretion in THP-1 human monocytes with an IC50 of 4.4 μM. In mice, GHN105 reduces serum levels of IFN-β, IL-6, and CXCL10, and alleviates colitis in a DSS-induced acute colitis mouse model. Additionally, GHN105 demonstrates favorable pharmacokinetic properties in mice, with an oral bioavailability of 43% and a half-life of 1.1 hours.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | GHN105 is an orally active STING inhibitor that suppresses STING-dependent IFN-β secretion in THP-1 human monocytes with an IC50 of 4.4 μM. In mice, GHN105 reduces serum levels of IFN-β, IL-6, and CXCL10, and alleviates colitis in a DSS-induced acute colitis mouse model. Additionally, GHN105 demonstrates favorable pharmacokinetic properties in mice, with an oral bioavailability of 43% and a half-life of 1.1 hours. |
| Molecular Weight | 800.89 |
| Formula | C41H56N2O14 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.